Xeris Biopharma Holdings, Inc. XERS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.23M-79.8% | $11.08M+1,684% | $621K+132% | -$1.93M+79.1% | -$9.22M-80.3% | ||
| $337K+0.6% | $335K-0.9% | $338K+4.0% | $325K+3.2% | $315K+0.6% | ||
| $4.14M-21.5% | $5.27M-31.0% | $7.64M+52.6% | $5.01M+12.7% | $4.44M+23.6% | ||
| $889K+2.7% | $866K+8.3% | $800K0.0% | $800K-5.2% | $844K+2.4% | ||
| $5.25M— | —— | $703K-89.5% | $6.72M+13.6% | $5.92M— | ||
| -$851K-121% | $4.01M-1.8% | $4.09M-46.1% | $7.57M+109% | $3.62M+15.3% | ||
| $4.25M+350% | -$1.7M-185% | $2M+145% | -$4.43M-209% | $4.06M+178% | ||
| -$1.5M-140% | $3.7M— | —— | —— | -$8.58M-302% | ||
| -$4.68M-301% | $2.34M+686% | $297K— | $0-100% | $1.36M+140% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$145K— | —— | $5.15M+2,009% | -$270K+82.4% | -$1.53M-593% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| $163K+7.9% | $151K+7.9% | $140K+9.4% | $128K+8.5% | $118K+8.3% | ||
| -$434K-2.8% | -$422K-2.4% | -$412K-5.6% | -$390K-10.8% | -$352K— | ||
| $9.87M-50.8% | $20.04M+8.7% | $18.43M+10,027% | $182K+102% | -$10.03M— | ||
| -$325K+2.4% | -$333K-369% | -$71K+74.6% | -$279K-2,046% | -$13K-100% | ||
| $847K+45.0% | $584K-88.7% | $5.16M+431% | $972K-80.0% | $4.86M+1,159% | ||
| $17.02M+1,005% | $1.54M+222% | $478K-44.4% | $860K-89.2% | $8M+4,718% | ||
| -$8.84M— | —— | $13.85M— | —— | -$3.14M-888% | ||
| $708K-96.4% | $19.44M-39.6% | $32.21M+3,712% | $845K+106% | -$13.18M-206% | ||
| $5.35M-23.1% | $6.95M-1.8% | $7.08M-45.9% | $13.09M— | $0-100% | ||
| $889K+2.7% | $866K+8.3% | $800K0.0% | $800K-5.2% | $844K+2.4% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| -$246K— | —— | —— | —— | $622K-49.1% | ||
| $6.26M— | —— | $11.93M+75.6% | $6.8M+312% | $1.65M-70.3% | ||
| -$434K-2.8% | -$422K-2.4% | -$412K-5.6% | -$390K-10.8% | -$352K— | ||
| -$145K— | —— | $5.15M+2,009% | -$270K+82.4% | -$1.53M-593% | ||
| $163K+7.9% | $151K+7.9% | $140K+9.4% | $128K+8.5% | $118K+8.3% | ||
| -$325K+2.4% | -$333K-369% | -$71K+74.6% | -$279K-2,046% | -$13K+94.1% | ||
| -$434K-2.8% | -$422K-2.4% | -$412K-5.6% | -$390K-10.8% | -$352K— | ||
| $7.33M— | —— | —— | —— | $0— | ||
| $0— | —— | —— | $11.96M+275% | $3.19M— | ||
| $0— | —— | $22K-87.8% | $180K+81.8% | $99K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Xeris Biopharma Holdings, Inc. generate?
- Xeris Biopharma Holdings, Inc. (XERS) generated $48.5M in operating cash flow over the trailing twelve months.
- Where does Xeris Biopharma Holdings, Inc.'s cash flow data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
